Table 1. Selection criteria devised for the review.

FSHD: Facioscapulohumeral muscular dystrophy; SMA: spinal muscular atrophy; DMA: Duchenne muscular dystrophy; HD: Huntington's disease

Criteria	Inclusion	Exclusion
Population	Patients diagnosed with rare genetic muscle-wasting disorders (e.g., FSHD, SMA, DMD, HD)	Patients without a diagnosis of rare genetic muscle-wasting disorders
Intervention	Physiotherapeutic interventions, including structured exercise programs, home-based training, and intensive physiotherapy regimens	Studies focused solely on pharmacological treatments or other non-physiotherapeutic interventions
Comparator	Comparator groups included no intervention, standard care, or alternative exercise modalities	Studies lacking a comparator group or using non-standardized comparators
Outcome	Measures of motor function improvements (primarily 6MWT), other functional assessments, muscle strength parameters, and quality of life measures	Studies not measuring motor function or related outcomes or using non-validated outcome measures
Study design	Randomized controlled trials (RCTs), cohort studies, and other comparative observational studies	Case reports, case series, reviews, and editorials
Language	Studies published in English	Studies published in languages other than English
Publication date	Studies published from inception to June 2024	Studies published outside the predefined publication date range